Impact of Preoperative Tumor Size on Prognosis of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinomas.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
25
11
2022
accepted:
08
08
2023
medline:
8
11
2023
pubmed:
2
9
2023
entrez:
1
9
2023
Statut:
ppublish
Résumé
Tumor size (TS) is a well-established prognostic factor of pancreatic ductal adenocarcinoma (PDAC). However, whether a uniform treatment strategy can be applied for all resectable PDACs (R-PDACs) and borderline resectable PDACs (BR-PDACs), regardless of TS, remains unclear. This study aimed to investigate the impact of preoperative TS on surgical outcomes of patients with R-PDACs and BR-PDACs. Chart data from three institutions were reviewed to select patients who underwent pancreatectomy for R-PDACs and BR-PDACs between January 2006 and December 2020. The patients were divided into TS TS of 35 mm and 24 mm was the best cutoff value in R-PDAC and BR-PDAC, respectively. The R1 rate was higher in the TS Larger TS was associated with a higher R1 rate and is a worse prognostic factor in patients with R-PDAC.
Sections du résumé
BACKGROUND
BACKGROUND
Tumor size (TS) is a well-established prognostic factor of pancreatic ductal adenocarcinoma (PDAC). However, whether a uniform treatment strategy can be applied for all resectable PDACs (R-PDACs) and borderline resectable PDACs (BR-PDACs), regardless of TS, remains unclear. This study aimed to investigate the impact of preoperative TS on surgical outcomes of patients with R-PDACs and BR-PDACs.
METHODS
METHODS
Chart data from three institutions were reviewed to select patients who underwent pancreatectomy for R-PDACs and BR-PDACs between January 2006 and December 2020. The patients were divided into TS
RESULTS
RESULTS
TS of 35 mm and 24 mm was the best cutoff value in R-PDAC and BR-PDAC, respectively. The R1 rate was higher in the TS
CONCLUSION
CONCLUSIONS
Larger TS was associated with a higher R1 rate and is a worse prognostic factor in patients with R-PDAC.
Identifiants
pubmed: 37658273
doi: 10.1245/s10434-023-14219-3
pii: 10.1245/s10434-023-14219-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8621-8630Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023. Society of Surgical Oncology.
Références
Fogel EL, Shahda S, Sandrasegaran K, et al. A multidisciplinary approach to pancreas cancer in 2016: a review. Am J Gastroenterol. 2017;112:537–54.
doi: 10.1038/ajg.2016.610
pubmed: 28139655
pmcid: 5659272
Motoi F, Ishida K, Fujishima F, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol. 2013;20:3794–801. https://doi.org/10.1245/s10434-013-3129-9 .
doi: 10.1245/s10434-013-3129-9
pubmed: 23838925
Motoi F, Satoi S, Honda G, et al. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. J Gastroenterol. 2019;54:194–203.
doi: 10.1007/s00535-018-1506-7
pubmed: 30182219
Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.
doi: 10.1016/S0140-6736(16)30583-9
pubmed: 27265347
National Comprehensive Cancer Network. NCCN practice guidelines for pancreatic cancer, version 1.2021-October 23, 2020. https://www2.tri-kobe.org/nccn/guideline/archive/pancreas2021/english/pancreatic.pdf Accessed 23 Oct 2022.
Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035–46. https://doi.org/10.1245/ASO.2006.08.011 .
doi: 10.1245/ASO.2006.08.011
pubmed: 16865597
Katz M H, Pisters P W, Evans D B, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206:833-46; discussion 46-8.
Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1727–33. https://doi.org/10.1245/s10434-009-0408-6 .
doi: 10.1245/s10434-009-0408-6
pubmed: 19396496
Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155:977–88.
doi: 10.1016/j.surg.2014.02.001
pubmed: 24856119
Okada K, Uemura K, Kondo N, et al. Preoperative risk factors for para-aortic lymph node positivity in pancreatic cancer. Pancreatology. 2021;21:606–12.
doi: 10.1016/j.pan.2021.01.022
pubmed: 33648880
Zhang W, Ji L, Wang X, et al. Nomogram predicts risk and prognostic factors for bone metastasis of pancreatic cancer: a population-based analysis. Front Endocrinol (Lausanne). 2021;12:752176.
doi: 10.3389/fendo.2021.752176
pubmed: 35356148
Lee KH, Lee JK, Choi DW, et al. Postoperative prognosis prediction of pancreatic cancer with seven microRNAs. Pancreas. 2015;44:764–8.
doi: 10.1097/MPA.0000000000000346
pubmed: 25906450
Toesca DAS, Jeffrey RB, von Eyben R, et al. Predicting pancreatic cancer resectability and outcomes based on an objective quantitative scoring system. Pancreas. 2019;48:622–8.
doi: 10.1097/MPA.0000000000001314
pubmed: 31091207
pmcid: 6553971
Murakami Y, Satoi S, Sho M, et al. National Comprehensive Cancer Network resectability status for pancreatic carcinoma predicts overall survival. World J Surg. 2015;39:2306–14.
doi: 10.1007/s00268-015-3096-3
pubmed: 26013206
Brierley JD, Gospodarowicz MK, Wittekind C. International Union Against Cancer (UICC). TNM Classification of Malignant Tumors. New York: Wiley 2017.
Motoi F, Kosuge T, Ueno H, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol. 2019;49:190–4.
doi: 10.1093/jjco/hyy190
pubmed: 30608598
Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.
doi: 10.1056/NEJMoa1304369
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.
doi: 10.1056/NEJMoa1011923
pubmed: 21561347
Fortner JG, Klimstra DS, Senie RT, Maclean BJ. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg. 1996;223:147–53.
doi: 10.1097/00000658-199602000-00006
pubmed: 8597508
pmcid: 1235090
Ansari D, Bauden M, Bergstrom S, et al. Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma. Br J Surg. 2017;104:600–7.
doi: 10.1002/bjs.10471
pubmed: 28177521
Hur C, Tramontano AC, Dowling EC, et al. Early pancreatic ductal adenocarcinoma survival is dependent on size: positive implications for future targeted screening. Pancreas. 2016;45:1062–6.
doi: 10.1097/MPA.0000000000000587
pubmed: 26692444
pmcid: 4912943
Franko J, Hugec V, Lopes TL, Goldman CD. Survival among pancreaticoduodenectomy patients treated for pancreatic head cancer <1 or 2 cm. Ann Surg Oncol. 2013;20:357–61. https://doi.org/10.1245/s10434-012-2621-y .
doi: 10.1245/s10434-012-2621-y
pubmed: 22941171
Jamieson NB, Foulis AK, Oien KA, et al. Peripancreatic fat invasion is an independent predictor of poor outcome following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2011;15:512–24.
doi: 10.1007/s11605-010-1395-4
pubmed: 21116727
Watanabe G, Ushida Y, Oba A, et al. Impact of tumor size on the outcomes of patients with resectable distal pancreatic cancer: lessons learned from a series of 158 radical resections. Ann Surg Oncol. 2022;29:378–88. https://doi.org/10.1245/s10434-021-10560-7 .
doi: 10.1245/s10434-021-10560-7
pubmed: 34403004
Saka B, Balci S, Basturk O, et al. Pancreatic ductal adenocarcinoma is spread to the peripancreatic soft tissue in the majority of resected cases, rendering the AJCC T-stage protocol (7th edition) inapplicable and insignificant: a size-based staging system (pT1: </=2, pT2: >2-</=4, pT3: >4 cm) is more valid and clinically relevant. Ann Surg Oncol. 2016;23:2010-8. https://doi.org/10.1245/s10434-016-5093-7
Gemenetzis G, Groot VP, Blair AB, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;270:340–7.
doi: 10.1097/SLA.0000000000002753
pubmed: 29596120
Inoue Y, Saiura A, Oba A, et al. Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: Intention-to-treat analysis compared with upfront surgery. J Hepatobiliary Pancreat Sci. 2021;28:143–55.
doi: 10.1002/jhbp.844
pubmed: 33058515
Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;40:1220–30.
doi: 10.1200/JCO.21.02233
pubmed: 35084987
Versteijne E, Vogel JA, Besselink MG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105:946–58.
doi: 10.1002/bjs.10870
pubmed: 29708592
Roland CL, Yang AD, Katz MH, et al. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol. 2015;22:1168–75. https://doi.org/10.1245/s10434-014-4192-6 .
doi: 10.1245/s10434-014-4192-6
pubmed: 25352267